So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic.Boothello, Rio S.; Sankaranarayanan, Nehru Viji; Afosah, Daniel K.; Karuturi, Rajesh; Al-Horani, Rami A.; Desai, Umesh R. researched the compound: 1,5-Dibromopentane( cas:111-24-0 ).COA of Formula: C5H10Br2.They published the article 《Studies on fragment-based design of allosteric inhibitors of human factor XIa》 about this compound( cas:111-24-0 ) in Bioorganic & Medicinal Chemistry. Keywords: fragment based drug design coagulation factors anticoagulants heparins allosterism; Allosterism; Anticoagulants; Coagulation factors; Fragment-based drug design; Heparins. We’ll tell you more about this compound (cas:111-24-0).
Human factor XIa (hFXIa) has emerged as an attractive target for development of new anticoagulants that promise higher level of safety. Different strategies have been adopted so far for the design of anti-hFXIa mols. including competitive and non-competitive inhibition. Of these, allosteric dysfunction of hFXIa′s active site is especially promising because of the possibility of controlled reduction in activity that may offer a route to safer anticoagulants. In this work, we assess fragment-based design approach to realize a group of novel allosteric hFXIa inhibitors. Starting with our earlier discovery that sulfated quinazolinone (QAO) bind in the heparin-binding site of hFXIa, we developed a group of two dozen dimeric sulfated QAOs with intervening linkers that displayed a progressive variation in inhibition potency. In direct opposition to the traditional wisdom, increasing linker flexibility led to higher potency, which could be explained by computational studies. Sulfated QAO 19S(I) was identified as the most potent and selective inhibitor of hFXIa. Enzyme inhibition studies revealed that 19S utilizes a non-competitive mechanism of action, which was supported by fluorescence studies showing a classic sigmoidal binding profile. Studies with selected mutants of hFXIa indicated that sulfated QAOs bind in heparin-binding site of the catalytic domain of hFXIa. Overall, the approach of fragment-based design offers considerable promise for designing heparin-binding site-directed allosteric inhibitors of hFXIa.
In some applications, this compound(111-24-0)COA of Formula: C5H10Br2 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.
Reference:
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis—I. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations,
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis